阿达木单抗治疗中重度银屑病的PK/PD特征与治疗药物监测应用
Pharmacokinetic/pharmacodynamic characteristics of adalimumab in moderate-to-severe psoriasis and its therapeutic drug monitoring applications
阿达木单抗作为全球首个获批上市的抗肿瘤坏死因子 α(tumor necrosis factor-α,TNF-α)单克隆抗体,已成为中重度银屑病的一线治疗选择。然而,该药物在银屑病患者群体中的药代动力学/药效动力学(pharmacokinetics/pharmacodynamics,PK/PD)特征尚未完全阐明。本文比较系统地综述了阿达木单抗在中重度银屑病治疗中的 PK 及其 PD 特性,重点探讨了抗药抗体形成和体质量等患者特异性因素对药物暴露的影响,并分析了治疗药物监测在银屑病治疗中的临床应用价值及优化策略,强调了建立银屑病特异性药物浓度-疗效关系模型和治疗窗的重要价值,以期为今后开展大样本临床研究提供明确方向,对银屑病个体化精准治疗策略的制定和实施提供指导。
As the first anti-TNF-α monoclonal antibody approved for clinical use worldwide, adalimumab has become a first-line treatment for moderate-to-severe psoriasis. However, this drug's pharmacokinetic (PK) and pharmacodynamic (PD) characteristics in psoriasis patients have not yet been fully elucidated. This article systematically reviews the PK and PD properties of adalimumab in the treatment of moderate-to-severe psoriasis, with a focus on the impact of patient-specific factors such as anti-drug antibody formation and body weight on drug exposure. Additionally, it analyzes the clinical application value and optimization strategies of therapeutic drug monitoring (TDM) in psoriasis treatment. This review emphasizes the importance of establishing psoriasis-specific drug concentration-efficacy relationship models and therapeutic windows, aiming to provide clear directions for future large-scale clinical studies and to guide the development and implementation of personalized precision treatment strategies for psoriasis.
| [1] |
刘迎春, 杨伟, 张晓东. 银屑病诱发因素及其共患病的研究进展[J].中国临床实用医学, 2023, 14(2): 77-80. |
| [2] |
刘紫欣, 申琳. 生物制剂治疗银屑病的效果及安全性研究进展[J].中国医药导报, 2024, 21(30): 65-69,78. |
| [3] |
中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂及小分子药物治疗指南 (2024 版)[J].中华皮肤科杂志, 2024, 57(11): 976-997. |
| [4] |
|
| [5] |
Saeki H, Mabuchi T, Asahina A, |
| [6] |
|
| [7] |
|
| [8] |
Wang W, |
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
European Medicines Agency. Humira: summary of product characteristics[EB/OL]. (2021-07-26)[2024-01-17].https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf |
| [14] |
|
| [15] |
U. S. Food and Drug Administration. Clinical pharmacology biopharmaceutics review(s) for Amjevita (adalimumab-atto)[EB/OL]. (2016-09-23)[2024-01-17].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761024Orig1s000ClinPharmR.pdf |
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
丁肖梁, 缪丽燕. 基于治疗药物监测优化阿达木单抗治疗: 当前证据和展望[J].中国循证医学杂志, 2023, 23(1): 85-93. |
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
中国炎症性肠病诊疗质控评估中心, 中华医学会消化病学分会炎症性肠病学组. 生物制剂治疗炎症性肠病专家建议意见[J].中华炎性肠病杂志, 2021, 5(3): 193-206. |
| [35] |
|
| [36] |
|
| [37] |
|
国家自然科学基金面上项目(82173879)
苏州市姑苏卫生人才青年拔尖人才项目(GSWS2022040)
苏州大学附属第二医院学科建设托举项目(XKTJ-XK202406)
苏州大学附属第二医院科研预研基金(SDFEYBS2308)
苏州市重点实验室建设项目(SZS2025012)
/
| 〈 |
|
〉 |